QTNT Quotient Limited

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Date	Price Target	Rating	Analyst
12/3/2021	$4.00 → $3.50	Neutral	Goldman Sachs
8/6/2021	$5.00 → $4.50	Neutral	Goldman Sachs

Quotient Limited

Peers

Recent Analyst Ratings for Quotient Limited

Quotient Limited Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3: New insider Quotient Holdings Gp, Llc claimed ownership of 17,020,000 shares

SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 17,247,931 units of Ordinary Shares

SEC Form 4: Hallsworth Frederick converted options into 438 units of Ordinary Shares, increasing direct ownership by 8% to 6,186 units

SEC Form 4: Larue Catherine converted options into 438 units of Ordinary Shares, increasing direct ownership by 37% to 1,618 units

SEC Form 4: Bechu Sophie converted options into 438 units of Ordinary Shares, increasing direct ownership by 381% to 553 units

SEC Form 4: Bonasso Vittoria converted options into 167 units of Ordinary Shares, increasing direct ownership by 75% to 390 units

SEC Form 4: Von Prondzynski Heino converted options into 1,004 units of Ordinary Shares, increasing direct ownership by 9% to 11,582 units

SEC Form 4: Buckle Isabelle converted options into 438 units of Ordinary Shares, increasing direct ownership by 21,900% to 440 units

SEC Form 4: Aebischer Thomas converted options into 438 units of Ordinary Shares, increasing direct ownership by 127% to 783 units

SEC Form 4: Buckle Isabelle sold $892 worth of Ordinary Shares (1,014 units at $0.88), decreasing direct ownership by 100% to 2 units